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dence of a survival benefit of continuous hemodiafiltrationA randomized clinical trial of continuous versus intermittent
compared with IHD. This study did not control for other majordialysis for acute renal failure.
clinical decisions or other supportive management strategiesBackground. Acute renal failure (ARF) requiring dialysis
that are widely variable (for example, nutrition support, hemo-in critically ill patients is associated with an in-hospital mortal-
dynamic support, timing of initiation, and dose of dialysis) andity rate of 50 to 80%. The worldwide standard for renal replace-
might materially influence outcomes in ARF. Standardizationment therapy is intermittent hemodialysis (IHD). Continuous he-
of several aspects of care or extremely large sample sizes willmodialysis and hemofiltration techniques have recently emerged
be required to answer optimally the questions originally posedas alternative modalities. These two therapies have not been
by this investigation.directly compared.
Methods. A multicenter, randomized, controlled trial was con-
ducted comparing two dialysis modalities (IHD vs. continuous
hemodiafiltration) for the treatment of ARF in the intensive Despite advances in intensive care unit (ICU) and dia-care unit (ICU). One hundred sixty-six patients were random-
lytic technology over the past four decades, mortality ratesized. Principal outcome measures were ICU and hospital mor-
associated with acute renal failure (ARF) remain distress-tality, length of stay, and recovery of renal function.
Results. Using intention-to-treat analysis, the overall ICU and ingly high. Depending on the etiology of ARF and comor-
in-hospital mortalities were 50.6 and 56.6%, respectively. Con- bid conditions, in-hospital mortality rates range from ap-
tinuous therapy was associated with an increase in ICU (59.5 proximately 30% in nephrotoxic drug-induced ARF to 90%vs. 41.5%, P  0.02) and in-hospital (65.5 vs. 47.6%, P  0.02)
or more when ARF is accompanied by respiratory, he-mortality relative to intermittent dialysis. Median ICU length
patic, or other organ system failure [1–4]. The worldwideof stay from the time of nephrology consultation was 16.5 days,
and complete recovery of renal function was observed in 34.9% standard of care for ARF requiring dialysis in the ICU
of patients, with no significant group differences. Despite ran- is intermittent hemodialysis (IHD). Continuous hemodi-
domization, there were significant differences between the alysis, hemofiltration, and hemodiafiltration techniquesgroups in several covariates independently associated with
[hereafter termed continuous renal replacement thera-mortality, including gender, hepatic failure, APACHE II and
pies (CRRT)] have recently emerged as alternative dia-III scores, and the number of failed organ systems, in each
instance biased in favor of the intermittent dialysis group. Using lytic modalities for critically ill patients with severe ARF.
logistic regression to adjust for the imbalances in group assign- To date, published comparisons of CRRT and IHD
ment, the odds of death associated with continuous therapy have shown favorable trends in survival, improved con-was 1.3 (95% CI, 0.6 to 2.7, P  NS). A detailed investigation
trol of volume overload and azotemia, and greater hemo-of the randomization process failed to explain the marked
dynamic stability with CRRT, although most have com-differences in patient assignment.
Conclusions. A randomized controlled trial of alternative pared CRRT in centers with extensive experience to
dialysis modalities in ARF is feasible. Despite the potential ad- historical controls [5–8]. No direct controlled compari-
vantages of continuous techniques, this study provides no evi- sons have been made between these two therapies.
To establish a valid comparison between dialytic ther-
apies, a randomized controlled trial was designed withKey words: hemodialysis, dialysis modalities, CAPD, continuous he-
modiafiltration, renal replacement therapy, intensive care. the following major goals: (1) to determine which dialytic
modality was superior in terms of ICU and in-hospitalReceived for publication July 10, 2000
survival, length of stay (LOS), and ultimate recovery ofand in revised form March 12, 2001
Accepted for publication March 26, 2001 renal function; and (2) to determine the relative influence
of comorbid conditions and severity of illness on out- 2001 by the International Society of Nephrology
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comes in ARF. The sample size was determined based crylonitrile) membranes were employed in IHD patients.
on the hypothesis that CRRT would result in a reduction The duration of IHD treatments was determined by the
in ICU mortality for ARF requiring dialysis from 70 to nephrologist based on an estimate of the catabolic state,
50% with two-tailed   0.05 and 1-  0.80. and ranged from three to four hours. Fluid removal per
session was prescribed on an evaluation of fluid status
with an aim to optimize fluid balance. When available,METHODS
estimates of fluid balance were guided by central venous
Study subjects pressure or pulmonary capillary wedge pressures.
We considered all adult ICU patients with ARF in Hemodiafiltration (hemodialysis hemofiltration) was
whom a nephrology service consultation was obtained prescribed for all patients in the CRRT arm. During the
at four academic medical centers in Southern California first two years of the study, continuous arteriovenous he-
(University of California, San Diego; U.S. Naval Medical modiafiltration (CAVHDF) with arteriovenous access
Center, San Diego; Veterans Administration Medical (single-lumen catheters placed in the femoral artery
Center, San Diego; and University of California, Irvine, and a central vein) was performed. Thereafter, continu-
CA, USA) between January 1991 and September 1995. ous venovenous hemodiafiltration (CVVHDF) was pre-
ARF was defined using standard laboratory parameters.
scribed, using one of two available pump-driven devices
For patients with no prior history of kidney disease or
(Hospal BSM-22 pump; Hospal Inc., Lyon, France; andavailable laboratory values, ARF was defined by a blood
Baxter BM-11; Baxter Inc., McGaw Park, IL, USA) andurea nitrogen (BUN) 40 mg/dL (140 mol/L) or a
a dual-lumen intravenous catheter. Hemodiafiltrationserum creatinine of 2.0 mg/dL (177 mol/L). For pa-
was accomplished using polysulfone or polyacrylonitriletients with available baseline laboratory values, ARF
membranes, blood flow rates of 100 mL/min, dialysatewas defined by a sustained rise in serum creatinine of
flow rates of 16.7 mL/min (1 L/hour), and ultrafiltration1 mg/dL (88.4 mol/L) compared with baseline. Pa-
rates of 400 to 800 mL/hour. The desired fluid balancetients were deemed to have pre-existing chronic renal
was maintained by administration of an hourly infusioninsufficiency (CRI) if they had a baseline creatinine of
rate of replacement fluid given prefilter. Systemic hepa-2.0 mg%. A patient was considered for enrollment if
rin, regional citrate, or saline flushes were variably em-in the judgment of the treating nephrologist he or she
ployed for anticoagulation in CRRT, depending on therequired dialysis and if the mean arterial blood pressure
treating physician’s judgment and hospital protocol. Pa-was 70 mm Hg with or without pressor support in the
tients were permitted to cross over from one therapy toeight hours preceding randomization. Exclusion criteria
included previous dialysis for acute or chronic renal fail- the other based on the following criteria: (1) lack of
ure, kidney transplantation, ARF from urinary tract ob- adequate arterial vascular access for CAVHDF (CRRT
struction, or a volume-responsive prerenal state. Indica- to IHD), (2) intolerance of the procedure (inability to
tions for dialysis were similar at all four centers and perform an adequate dialysis treatment because of in-
included uremia, electrolyte abnormality, diuretic unre- tradialytic hypotension despite use of fluid boluses and
sponsive fluid overload, acid-base imbalance, and a pressors; IHD to CRRT), (3) need for mobility (require-
marked catabolic state, for example, burns. Informed ment for patient to be out of bed in a chair; CRRT to
consent was obtained from all study participants or their IHD), or (4) transfer from the ICU (CRRT to IHD).
next of kin. The study was approved by the institutional As the duration of dialysis was variable, an adequate trial
review boards of all participating hospitals. Patients were of therapy was defined as a minimum exposure of 25 hours
followed prospectively from the time of initial nephrol- for CRRT and two treatments of three hours or more of
ogy service consultation through hospital discharge. duration each for IHD.
Treatment assignments
Clinical data
Patients at each center were randomized to IHD or
Baseline vital signs, hemodynamic, and laboratory dataCRRT with the intervention assignment generated by a
were recorded for the first ICU day (most extreme val-computerized random number generator with separate
ues) and every day (every 12 hours) from the time oflists at each center. Dialysis treatment was initiated in
nephrology consultation. Serial Acute Physiology andall patients by the consulting nephrologist. IHD was per-
Chronic Health Evaluation (APACHE) II and III scoresformed using ultrafiltration-controlled machines, hepa-
were computed for each day in the ICU to assess changerin anticoagulation, bicarbonate-based dialysate, dialy-
in severity of illness [9, 10]. We determined the numbersate flow rates of 500 mL/min, and blood flow rates of 200
of organ systems in failure (OSF) based on a modificationto 300 mL/min using temporary dual-lumen catheters.
of the criteria of Seneff and Knaus [10]. The criteriaCellulosic (cuprophan, cellulose acetate) and noncellu-
losic (polysulfone, polymethylmethacrylate, and polya- used for each OSF [11] are described in the Appendix.
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Table 1. Characteristics of patients at randomizationDefinitions
IHD CRRT P valueThe primary outcome measure was all-cause ICU mor-
N patients 82 84tality. In-hospital mortality, ICU and hospital LOS, and
Demographicsrecovery of renal function were secondary outcome mea-
Mean age years 56.3 54.5 NS
sures. Complete recovery of renal function was defined % Male 68.3 83.3 .023
% White 53.7 58.3 NSas the return of serum creatinine to 2.0 mg/dL
% Surgical 31.7 23.8 NS(177 mol/L) or return to baseline creatinine concentra-
% ARF on CRF 31.7 23.8 NS
tion for patients with acute on chronic renal disease. % Oliguric 24.4 20.2 NS
% Ventilated 56.7 64.1 NSRecovery was deemed to be partial when the above
% DNR before consult 1.2 7.1 NSconditions were not met, but the patient was no longer
% ARF 1st ICU day 42.7 45.2 NS
dialysis dependent. Etiology of ARF was classified as Etiology of ARF
% Ischemic 53.7 53.6 NSischemic acute tubular necrosis (ATN), nephrotoxic
% Nephrotoxic 14.6 17.9 NSATN, multisystem disorder, or uncertain.
% Multisystem/GN 7.3 7.1 NS
% Unknown 24.4 21.4 NS
Statistical analysis Severity of illness scores
% Liver failure 29.3 42.9 .05All data were entered into PC!Info (Retriever Data APACHE II 23.7 25.5 NS
Systems, Seattle, WA, USA) and converted into SAS APACHE III 87.7 96.4 .045
N organs systems failing 3 3.2 NS(SAS Institute, Cary, NC, USA) data sets for analysis.
Renal function markersMeans of continuous data were compared with the Stu- Urine output L/24 h 0.93 0.88 NS
dent t test. Categorical variables were compared with BUN mg/dL 78.5 87.1 NS
Creatinine mg/dL 4.6 4.4 NSthe 	2 goodness-of-fit and Maentel-Haenszel 	2 test for
Abbreviations are: IHD, intermittent hemodialysis; CRRT, continuous renaltrend. Multivariable stepwise logistic-regression analysis
replacement therapy; ARF, acute renal failure; CRF, chronic renal failure; DNR,was performed to adjust for the intergroup imbalance do not resuscitate; ICU, intensive care unit; GN, glomerulonephritis; BUN, blood
urea nitrogen; NS, not significant.in explanatory variables. The primary analyses used the
intent-to-treat population. Prespecified subgroup analy-
ses were restricted to (1) patients who completed an
(N  3), concurrent enrollment in other ICU protocols
adequate trial of therapy and (2) patients who crossed
(N  2), lack of familiarity with study procedures (N 
over from one treatment to another. Two-tailed P values 3), and unsuitable patient for social reasons (N  2).
0.05 were considered statistically significant. The 82 patients who were excluded by the physicians
were further compared with those who were randomized,
and no significant differences were seen at the time ofRESULTS
consultation in the key demographic variables shown inStudy participants and randomization
Table 1 (data not shown). The 166 randomized patients
At the four centers participating in the trial, 718 pa- enrolled are included in the analyses presented here. Of
tients were consulted on for 746 episodes of ARF and the 166 patients randomized, 82 were assigned to IHD
374 patients were dialyzed. Of these, 166 (44.4%) were and 84 were assigned to CRRT. In the CRRT arm, the
randomized. Of the 208 non-randomized patients who majority (84.5%) of patients were treated with pumped
received dialysis, 78 (20.9%) did not meet the hemody- systems (CVVHDF). Figure 1 shows the breakdown of
namic eligibility criteria. Thirty (8.0%) were refused entry all randomized patients enrolled in the trial. No patients
into the study by the treating physician. Fifty-two (13.9%) were lost from the trial because of incomplete follow-
were not enrolled at the discretion of the consulting up. Fourteen patients received no treatment after ran-
nephrologist. Sixteen (4.3%) refused directly or via the domization (CRRT 11 vs. IHD 3, P  0.05) because of
next of kin. Ten (2.7%) lacked an arterial access for an improvement in renal function in seven patients and
CAVHDF, and 22 (5.9%) were enrolled in another study death in seven patients before dialytic therapy was
or did not participate for other miscellaneous reasons. started. Twenty-one (12.7%) patients did not meet the
We were able to ascertain the reasons for nonenrollment criteria outlined for an adequate trial of therapy. The
in 77 of the 82 patients excluded by the physicians. Rea- reasons for a limited treatment time were improvement
sons for nonenrollment by the participating physicians in renal function in 9 patients and death in 12 patients
included (1) emergent indication for dialysis (P  60), (six in each group). Therefore, 35 (21.1%) patients failed
that is, marked hyperkalemia (N  7), acidosis (N  3), to complete the trial (no treatment  limited treatment
uremic complications (N  18), and volume overload groups). Thirty-two (19.3%) patients crossed over from
(N  19); (2) specific request of transplant surgeons for one therapy to the other, 15 from IHD to CRRT and
heart, lung, and liver transplant patients (N  7); and 17 from CRRT to IHD. Table 1 compares the baseline
clinical characteristics of the two treatment groups. De-(3) other reasons (N 10), that is, risk of hypotension
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Fig. 1. Study enrollment pattern and distribution of randomized patients at each center.
spite randomization, there were significant differences generated by computer and a large block size (N  10)
was used. There were separate lists generated for eachin several key explanatory variables, including the pro-
portion of men (83.3% in CRRT vs. 68.3% in IHD, P  center. Each center had the allocation in sealed opaque
envelopes through which the assignment was not visible.0.02) and the proportion with hepatic failure (42.9% in
CRRT vs. 29.3% in IHD, P  0.05). There were trends The master list of random assignment was kept only at
the statistician’s home. Additionally, there were multiplein the three severity-of-illness measures, all of which
suggested that patients assigned to CRRT were in fact physicians involved in the study at each center so that
no single physician or other provider had the opportunitysicker: mean APACHE II (25.5 in CRRT vs. 23.7 in
IHD, P  0.08) and APACHE III (96.4 in CRRT vs. of knowing (or guessing) what was the next patient’s
87.7 in IHD, P  0.045) score, and the mean number of assignment. Finally, we carried out an analysis of the
failing organ systems (3.2 in CRRT vs. 3.0 in IHD, P  sequence of enrollment of all persons in relationship to
0.121); 74.2% of the IHD group and 78.5% of the CRRT those who were randomized. There was no evidence
group (P  NS) were volume overloaded (defined as that eligible patients were systematically withheld from
clinical evidence of fluid overload and fluid gain 4 L randomization in preference for either of the two proto-
from baseline) at the time of initiation of dialysis. We cols. Implementation of the randomization assignment
investigated the possible reasons for these imbalances was also uniform for all patients. There was no discrep-
following randomization. These included (1) center effect, ancy in assignments stated on the randomization lists
(2) compromised randomization, and (3) chance. The and the initial therapy given to the patient. These internal
distribution of patients into IHD and CRRT arms was investigations indicate that randomization was not com-
uniform at all four centers (	2, P  NS), and there were promised. Therefore, the observed differences in patient
large differences in APACHE III scores between the characteristics by treatment assignment are most likely
CRRT and IHD groups at three of the four centers, different by chance alone.
although none were statistically different due to small
ICU and in-hospital mortalitysample size. There were three possible reasons for a
failure of randomization: (1) improper random sequence In the intent-to-treat population, overall ICU and in-
hospital mortality was 50.6 and 56.6%, respectively, wellgeneration, (2) inadequate allocation concealment, and
(3) problematic implementation. We investigated each below levels typically reported in the literature. On unad-
justed analysis, 28 day all cause and ICU mortality wereof these possibilities. The randomization sequence was
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Fig. 2. Effect of severity of illness on mortal-
ity in the intermittent hemodialysis () and
continuous renal replacement therapy ( )
groups.
Table 2. CRRT versus IHD for ARF: Prediction of ICU mortalitysimilar and were significantly increased with CRRT com-
pared with IHD (59.5 vs. 41.5%, P  0.02), as was in- % ICU
Variable Parameter N mortality OR CI Phospital mortality (65.5 vs. 47.6%, CRRT vs. IHD, P 
Gender Female 40 40 1.00 — —0.02). Results were similar when the analysis was re-
Male 126 54 1.63 0.65–4.13 NSstricted to patients who had received adequate trial of
Liver failure No 106 35.9 1.00 — —
therapy (ICU mortality 60.9 vs. 41.8%, CRRT vs. IHD, Yes 60 76.7 2.34 1.003–5.46 0.049
APACHE III 
79 65 26.2 1.00 — —P  0.028; hospital mortality 65.6 vs. 49.3%, CRRT vs.
80–100 44 47.7 1.82 0.75–4.43 NSIHD, P  0.058). When evaluating prespecified sub-
100 57 80.7 3.46 1.23–9.70 0.019
groups, ICU and hospital mortality were 28.9 and 38.5%, OSF 1–2 59 25.4 1.00 — —
3 51 47.1 1.95 0.80–4.74 NSrespectively, for the patients who only received IHD
4 56 80.4 3.40 1.15–10.09 0.027versus 68.1 and 72.3% for those who were treated with
Group IHD 82 41.5 1.00 — —
CRRT alone (P 0.001 for both ICU and hospital mor- CRRT 84 59.5 1.58 0.74–3.35 NS
tality). In contrast, patients who crossed over from IHD Abbreviations are in Table 1 and: OSF, organ system failure; OR, odds ratio;
CI, confidence interval.to CRRT had the highest mortality rates (ICU and hospi-
tal 86.7%) in comparison to those who crossed over
from CRRT to IHD (ICU 41.2% and hospital mortality
47.1%; P  0.02). tality, the relative contribution of each of these variables
was evaluated in a multivariable stepwise logistic-regres-
Comorbid conditions and severity of illness sion analysis, including group assignment as an indepen-
Since there were significant differences in patient char- dent explanatory variable. Hepatic failure, APACHE III
acteristics between the two groups, we evaluated the asso- scores, and the OSF score were independently related
ciations of these characteristics with ICU and in-hospital to ICU mortality (Table 2). Gender and hepatic failure
mortality. Men were more likely to die during the study were correlated; men were twice as likely to have hepatic
than women (54 vs. 40%, P  0.054), as were patients failure as women, although the difference did not reach
with hepatic failure (76.4 vs. 35.1% in patients without statistical significance (	2, P  0.10). Randomization to
hepatic failure, P  0.05). When patients were stratified CRRT or IHD was not independently associated with
by ranking into tertiles based on their APACHE III mortality after adjustment for these unbalanced covari-
scores at the time of randomization, ICU and in-hospital ates, suggesting that the differences in mortality observed
mortality were directly related to the degree of severity
between CRRT and IHD could be attributable to comor-
of illness. A similar trend was observed when patients
bidity and severity of illness, rather than dialysis mod-were stratified based on the OSF score at the time of
ality. Indeed, the adjusted odds of death associated withrandomization. In a further evaluation of the association
CRRT was 1.58 (95% CI 0.7 to 3.3). A time-to-eventof severity of illness with mortality within the CRRT
analysis was conducted using proportional hazards (Cox)and IHD groups, within each stratum of APACHE III
regression. Using this alternative method, there was ascores there was no significant difference in mortality
significant increase in the hazard ratio, or unadjustedbetween CRRT and IHD (Fig. 2).
relative risk of death associated with CRRT (hazard ratio
Multivariable analysis 1.64, CI, 1.08 to 2.48, P  0.02). Again, adjustment by
APACHE III and other variables yielded the same con-As the differences in patient characteristics and sever-
ity of illness appeared to be major determinants of mor- clusions (hazard ratio 1.35, CI, 0.89 to 2.06, P  0.16).
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Renal recovery assigned to IHD averaged 5.25 IHD treatments and 7.0
CRRT treatments (for the 15 crossover patients) perOverall, 36.6% patients (70.7% of those who survived)
person per week. The 84 patients assigned to CRRThad a complete recovery of renal function, and there was
averaged 5.34 IHD treatments (for the 17 crossover pa-no difference between the two groups (34.9% in CRRT
tients) and 6.94 CRRT treatments per person per week.vs. 33.3% in IHD, P  NS). Using an intention-to-treat
The mean duration of each IHD (3.1 hours) and CRRTanalysis, 17% of patients assigned to IHD and 4% of
treatment (16.1 hours) was similar in the two groups.those assigned to CRRT were left with CRI (P  0.01)
Technical efficacy of the two modalities was assessed byat hospital discharge or death. There was no significant
evaluating the BUN and creatinine concentrations atdifference in the frequency of CRI in the ARF versus
various time points following initiation of dialysis. It isARF on CRI groups within each therapy assignment.
evident that the nature of IHD results in alternate peaksOf the surviving patients, 7% in the IHD and 14% in
and troughs of solute levels depending upon the fre-the CRRT group (P  NS) remained on maintenance
quency of dialysis, while CRRT is associated with adialysis at hospital discharge. However, continuous ther-
steady state level of solutes [12]. A comparison of meanapy was associated with a significantly higher rate of com-
daily BUN and creatinine levels between the two groupsplete renal recovery in surviving patients who received
from the first dialysis treatment for the first 10 days isan adequate trial of therapy with no crossover (CRRT
shown in Figure 3. Continuous therapy resulted in lower92.3% vs. IHD 59.4%, P  0.01). In addition, patients
solute levels despite higher mean BUN values at thewho crossed over from CRRT to IHD had a significantly
start of therapy. Mean dialyzer BUN clearance was 21.5higher rate of complete recovery than those crossing
mL/min in patients treated with CRRT. Predialysis andover from IHD to CRRT (CRRT to IHD 44.7% vs. IHD
post-dialysis BUN levels were not routinely availableto CRRT 6.7%, P  0.01). Severity of illness was an
to compute urea reduction ratios or Kt/V in the IHDimportant determinant of renal recovery. The lowest
patients. The efficacy of volume control in the two armsrates of renal recovery were observed among patients
was compared by evaluating the cumulative fluid balancewith APACHE III scores 100 (60.7% vs. 50.0% vs.
in each patient. Since CRRT techniques have an inherent25.0% for APACHE III scores
79, 80 to 100 and100,
advantage in this regard, we additionally assessed the
respectively, P  0.001). Similar findings were seen with
ability of each protocol to achieve the stated goal for
increasing APACHE II and OSF scores. Finally, renal
fluid removal. More than one fourth (28.8%) of the IHD
recovery was rare in patients who died. treatments were unable to achieve the stated fluid goals.
It is difficult to assess a similar parameter for CRRT,Length of stay
since the duration of CRRT typically far exceeds that
As the timing of nephrology consultation and patient of IHD, and short-term ultrafiltration goals are less well-
enrollment into the study varied in relationship to the defined. Fewer than 1 in 10 (9%) CRRT treatments fell
patient’s admission to the hospital and ICU, the LOS short of the desired ultrafiltration goal.
was calculated from the time of randomization. ICU
LOS was similar in both groups using an intent-to-treat Technical complications
analysis (CRRT 15.1 vs. IHD 16.7 days, PNS). Hospi- Data were accumulated on the incidence of technical
tal LOS was significantly reduced for patients who re- complications related to access, anticoagulation, and
ceived CRRT as the initial therapy only (CRRT 17.1 vs. pump use. For CRRT techniques, we distinguished be-
IHD 26.3 days, P  0.01). This difference in part may tween arteriovenous techniques (CAVHDF) and veno-
be related to the higher ICU mortality rate observed in venous techniques (CVVHDF) as the access and driving
the CRRT arm. Patients who received both therapies forces are different. Arterial access was difficult to obtain
had longer ICU and hospital lengths of stay. Higher in 3 out of 32 patients with CAVHDF and required
APACHE III and OSF scores were associated with multiple attempts. Difficulties in obtaining venous access
shorter LOS, reflecting higher mortality rates with higher were encountered in 5.3% cases of CAVHDF, 6.1%
scores. Similarly, survivors had longer ICU lengths of IHD, and 9.5% in CVVHDF. Arterial access clotting
stay than nonsurvivors. was seen in 0.3% of all cases, while venous access clotting
was more frequent and occurred in 1.5% of all cases, and
Control of azotemia and volume overload was equally frequent in the CRRT and IHD techniques.
Using an intention to treat analysis of the 166 random- Tubing disconnection was seen in 0.2% of IHD and
ized patients, we found that the total number of treat- 0.3% of CRRT. Blood loss 50 mL attributable to the
ments was slightly lower in the group assigned to CRRT procedure occurred in 0.25 of IHD and 6.3% of
(8.07) than in the group assigned to IHD (8.67), although CVVHDF procedures. Membrane leaks were seen in
the difference is not statistically significant (P  0.75). 0.2% of CVVHDF, 0.9% of CAVHDF techniques, and
were not observed in IHD. Restricting the analysis toAs some patients in each group crossed over, 82 patients
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Fig. 3. Control of blood urea nitrogen (BUN)
(A) and serum creatinine (B) during therapy
with IHD() and CRRT().
patients who only received IHD or CRRT (excluding Costs
crossovers), 0.8% of the IHD group and 1.9% of the Resource utilization per treatment day was calculated
CRRT group (P  NS) developed bleeding complica- to determine the labor costs (by prospectively document-
tions. One percent of the heparin anticoagulated IHD ing the time spent by nurses, technicians, physicians,
runs (N  205) versus 9.4% of heparin anticoagulated N  449) and material costs (equipment, disposables,
CRRT days (N  85) were complicated by bleeding solutions, N  1352). Material costs were significantly
(systemic or localized associated with high PTT 150 higher for CRRT ($338) than that for IHD ($66) with the
sec). All the bleeding complications were seen in heparin major contributor for CRRT being the dialysate (33% of
CAVHDF procedures. None of the citrate anticoagu- total cost) followed by the cost of the filters (20%) and
lated IHD (N  26) or CRRT days (N  284) had any the rental costs of infusion pumps (20%). The labor costs
episodes of bleeding, while 0.7% of the saline anticoagu- for IHD ($216) and CRRT ($205) were similar. The total
lated IHD (N 129), and none of the saline flush CRRT
direct cost per treatment was much higher for CRRT
(N 62) had bleeding complications. Metabolic compli-
($543) compared with IHD ($282); the overall cost ofcations were more common in CRRT than IHD: hyper-
dialysis also was affected by the number of treatments.natremia (defined as Na 145; IHD 12.0% vs. CRRT
The total direct cost of dialysis was affected by both the22.0%, P  0.001) and alkalemia (pH 7.44 and bicar-
cost per treatment and the number of treatments re-bonate 28; IHD 9.8% vs. CRRT 15.6%, P  0.02).
ceived. Using an intention-to-treat analysis of the 166Hypernatremia was more common in patients on saline
randomized patients, the total number of treatments wasflush or citrate anticoagulation (saline IHD 15.8% vs.
slightly lower in the group assigned to CRRT (7.9) thansaline CRRT 21.4, PNS; citrate IHD 11.1% vs. citrate
in the group assigned to IHD (8.4), although the dif-CRRT 26.8%, P  NS). Alkalemia was most commonly
ference was not statistically significant (P  0.77). Someseen in citrate anticoagulated procedures (citrate IHD
patients in each group crossed over, 82 patients assigned to29.6% vs. citrate CRRT 18.8%, P  NS), but was also
IHD averaged 5.8 IHD treatments and 2.6 CRRT treat-present in patients on heparin and saline flush anticoagu-
ments per person. The 84 patients assigned to CRRTlation. The incidence of hypernatremia was similar in
averaged 1.3 IHD treatments and 6.6 CRRT treatmentsCAVHDF (18.8%) and CVVHDF (23.0%, P  NS)
per person. Total per patient treatment costs for CRRTprocedures, while alkalemia was more common with
CAVHDF (21.2%) than CVVHDF (14.1%, P  NS). were $3946 and $3077 for IHD (P  NS).
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DISCUSSION transfer out of intensive care, improved hemodynamic
stability, and resolution of volume overload.Contemporary management of ARF requiring dialysis
It may be unrealistic to assume that a single decisionin the ICU includes a decision regarding the choice of
in the complex care of a critically ill patient could signifi-dialysis modality, including IHD, peritoneal dialysis, and
cantly influence survival. Mortality in the critically ill pa-continuous hemodialysis, hemofiltration, and hemodia-
tient is likely to be influenced by several factors unrelatedfiltration. This study was designed to assess whether the
to dialysis. It has been previously shown that the do-not-type of dialysis modality (CRRT or IHD) used to treat
resuscitate (DNR) status in the ICU setting influencesARF in the ICU setting affects mortality, length of stay,
the level of care administered and the eventual outcomeand the likelihood of recovery of renal function. We hy-
[16]. We found that 7.1% of CRRT and 1.2% of IHDpothesized that CRRT would be superior to IHD and
patients (P  NS) were made DNR prior to nephrologydesigned the trial to detect a 27% difference in ICU
consultation. A perception of futility, among other fac-mortality.
tors, may affect practice and reduce the effectivenessThe data show an overall mortality rate of 50.6%, con-
of any intervention. It also should be noted that othersiderably lower than the 60 to 80% rates reported in most
dialysis-related factors were not controlled for, includingpublished studies. This finding may be due to the clini-
the timing of initiation, frequency, intensity, membranecal trial effect reflecting an improved level of care or
choice, and dose of dialysis [17]. Although membranemay reflect the exclusion of patients too ill (hypotensive)
choice has been variably shown to affect outcome fromto be randomized [13]. ICU mortality was 59.5% with
ARF in recent studies, it is unlikely that membraneCRRT and 41.5% with IHD, a statistically significant
played a significant role in this study as all the CRRTand clinically important difference. On the surface, these
patients and the majority of IHD patients were treatedfindings support a survival advantage for IHD, although
with synthetic, noncellulosic membranes. Of course, afurther analysis provides an alternate explanation. It is
myriad of other conditions and their treatments (for ex-well recognized that severity of illness affects disease-
ample, antibiotics, pressor agents, nutrition support) also
specific outcomes in critically ill patients. In this study,
may limit the specificity of an intervention such as a
each of three indices of severity of illness (APACHE II change in dialysis modality. Swartz et al have recently
and III and OSF) and two other clinical factors signifi- validated this viewpoint based on a retrospective com-
cantly associated with mortality (male gender and he- parison of CVVH versus IHD at a single center [18].
patic failure) were not evenly distributed, with more Using a Cox proportional hazards model, they showed
severe nonrenal disease present in the patients random- that the sickest patients are more likely to receive CRRT
ized to CRRT [14, 15]. A detailed investigation failed as initial therapy and the underlying comorbidities ac-
to reveal any specific factors accounting for these differ- count for the difference in mortality observed in their
ences. A logistic regression analysis adjusting for these patients.
factors yielded a nonsignificant difference by treatment Mortality is an important outcome, although it may
assignment. Furthermore, within strata of APACHE II not be the most appropriate primary outcome for ARF,
and III scores, the relative mortality rates of CRRT and for many of the reasons cited previously in this article.
IHD were not significantly different. Additionally, sur- Recovery of renal function and the need for short- and
vival analysis of time to outcome (data not shown) did long-term dialysis may be more specific outcome mea-
not reveal any significant difference between the two sures to evaluate in the patient with ARF [19, 20]. Renal
modalities. This pattern was apparent even when pa- recovery was rare in patients who died; however, survi-
tients who did not receive any therapy in either group vors had varying levels of recovery of renal function,
were excluded from the analysis. Together these findings and this appeared to be related to modality. Complete
strongly suggest that the increased risk of death observed recovery of renal function was achieved more frequently
in the CRRT group was the direct result of nonrenal in patients on CRRT compared with IHD. The mecha-
disease and that no definite statement can be made re- nism for this finding is unknown, but clearly warrants fur-
garding the superiority of one modality or the other. ther study. Intermittent dialysis may be associated with
In our study, patients who crossed over from IHD to more frequent hemodynamic insults [21]. Alternatively,
CRRT had an increase in their APACHE and OSF improved control of azotemia, clearance of middle mole-
scores at the time of crossover, while those who crossed cules [22], and reduction in pulmonary, myocardial, gas-
over to IHD from CRRT had a decrease in their scores trointestinal, and other tissue edema may also play a role.
(data not shown). These findings also highlight the im- Technical complications were similar in both groups
portance of severity of illness and likely explain the phe- and were largely related to anticoagulant use. Despite the
nomenon described previously in this article among longer exposure to CRRT techniques, the overall fre-
crossover patients. Indeed, a change from CRRT to IHD quency of complications was similar in the two groups.
Although the daily cost for CRRT is more than that forrepresents a complex array of events that may include
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IHD, the difference in costs is largely related to the variable (for example, nutrition support, hemodynamic
support, timing of initiation, and dose of dialysis) andincreased expense of materials. At the time this study
was done, CRRT was not as widely used as it is today, might materially influence outcomes in ARF. Standard-
and the cost of materials has changed. Additionally, how ization of several aspects of care and a significantly larger
many filter kits are used can largely influence the costs sample will be required to answer optimally the ques-
for CRRT. As CRRT techniques gain wider acceptance tions originally posed by this investigation.
and methods to promote filter life are more universally
adapted, it is likely that this difference in overall costs ACKNOWLEDGMENTS
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APPENDIXlikely to have experienced unbalanced randomization
Criteria for organ system failuredue to chance. It could be argued that selection of pa-
Cardiovascular. Heart rate 
54 per min, mean arterial blood pres-tients excluded the majority of available patients because
sure
49 mm Hg, occurrence of ventricular tachycardia and/or ventric-
of hemodynamic instability or physician choice. How- ular fibrillation or other cardiac arrhythmias requiring continuous infu-
sion of antiarrhythmic, requirement for temporary pacemaker, intra-ever, our analysis shows that the patients excluded by
aortic balloon pump or ventricular assist devices.the physician’s choice were not significantly different
Neurological. Glasgow coma score (GCS)
6. When sedatives were
than those enrolled. CRRT is most commonly reserved used, these were recorded.
Renal. Blood urea nitrogen (BUN) 
40 mg/100 mL or creatininefor patients who are unable to receive IHD, and we had
2.0 mg/100 mL for patients with no previous history of renal disease,designed the protocol to exclude patients with MAP70
an increase in creatinine 1 mg% for patients with pre-existing renal
to avoid bias against IHD. CRRT is probably the most disease.
beneficial in patients who are hemodynamically unstable; Hematological. White blood cells (WBC) 
1000 mm3, platelets

20,000 mm3, hematocrit 
20% (not chronic renal failure), require-however, it is difficult to design a study that enrolls only
ment for platelet transfusions to maintain platelet levels20,000/mm3.this group of patients. Additionally, the wide variation Respiratory. Respiratory rate 
5/min or 49/min, Paco2 50
in practice of indications for and timing of initiation of mm Hg, Aado2 350 mm Hg, ventilator dependent after 24 hours of
OSF.dialysis is a major limitation. Standardization of dialytic
Liver. Clinical acute liver failure with elevations in bilirubin levelsand nondialytic management might have improved spec- (total and direct); aspartate aminotransferase (AST), alanine amino-
ificity for the intervention. However, there is no world- transferase (ALT), and alkaline phosphatase (AP), greater than two
times normal. Additionally, an increase in prothrombin time and INRwide agreement on most aspects of ARF management,
of1.5. For patients with pre-existing chronic liver disease, documentedincluding significant fundamental decision points, such evidence of worsened liver function and presence of encephalopathy.
as the optimal timing of initiation, frequency, membrane,
and dose of dialysis. Indeed, much of ARF practice has REFERENCES
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